Semaglutide is a GLP-1 receptor agonist drug available under brand names Ozempic, Wegovy, and Rybelsus, prescribed to treat type 2 diabetes and, more recently, obesity-related cardiovascular disease. Medicare coverage depends on the medical reason the drug is prescribed, not the drug itself.
Federal law historically blocked Medicare from paying for medications prescribed solely for weight loss. That changed in part with a new FDA approval and the Medicare GLP-1 Bridge program. Type 2 diabetes patients covered under Part D have had access to Ozempic for years. The cardiovascular indication for Wegovy opened a new coverage path for millions of seniors with obesity.
This guide breaks down every coverage scenario, the new $50-per-month Bridge program, eligibility rules, and what seniors without qualifying conditions pay out of pocket. By the end, readers will know exactly where they stand and what steps to take next.
Does Medicare Cover Semaglutide for Weight Loss?
Medicare coverage for semaglutide depends entirely on the medical diagnosis attached to the prescription, not on the drug name itself. For weight loss alone, federal law previously banned coverage. That ban has now partially lifted.
Medicare Part D covers semaglutide when prescribed for type 2 diabetes (branded as Ozempic) or for reducing cardiovascular risk in patients with obesity or overweight and known heart disease (branded as Wegovy). A prescription written solely for weight loss with no qualifying condition still falls outside standard Part D coverage. The Medicare GLP-1 Bridge program, launched July 1, 2026, now fills part of that gap for eligible beneficiaries at a $50-per-month copay.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1, triggering insulin release after meals while slowing gastric emptying. Novo Nordisk manufactures it under three brand names serving different conditions.
Ozempic is the injectable form approved for type 2 diabetes since 2017. Wegovy is the higher-dose injectable and tablet form approved for obesity and weight management. Rybelsus is the oral tablet form approved for type 2 diabetes. The active molecule is identical across all three brands. Dosing schedules and approved uses differ by brand and formulation.
What Conditions Does Medicare Cover Semaglutide For?
Medicare covers semaglutide for two FDA-approved indications: type 2 diabetes management and reduction of major cardiovascular events in adults with obesity or overweight who also have established heart disease. Prediabetes and weight loss alone are not covered indications.
The cardiovascular indication was approved by the FDA in March 2024. Wegovy, prescribed under this indication, became eligible for Medicare Part D coverage. Ozempic, prescribed for type 2 diabetes, has been covered by Part D plans since 2017. Off-label uses, including prediabetes management and cosmetic weight loss, require full out-of-pocket payment regardless of plan type.
What Are the Current Medicare Rules for Weight Loss Drugs?
Federal law explicitly prohibited Medicare from covering medications prescribed primarily for weight loss for decades, a restriction rooted in concerns about coverage priorities and drug spending. That restriction has begun to erode through new FDA indications and Congressional action.
The Inflation Reduction Act introduced caps on out-of-pocket drug spending. The 2024 FDA cardiovascular approval for Wegovy created the first legal pathway for Medicare to cover a GLP-1 specifically in obese patients. The Medicare GLP-1 Bridge program, running July 1, 2026 through December 31, 2027, extends coverage further. Compounded semaglutide remains excluded because it lacks an FDA-assigned National Drug Code.
Does Medicare Part D Cover Semaglutide?
Yes. Medicare Part D covers FDA-approved semaglutide formulations for qualifying medical conditions, specifically type 2 diabetes and cardiovascular disease risk reduction. Coverage requires the drug to appear on the plan’s formulary.
Ozempic appears on many Part D formularies as a diabetes medication. Wegovy, prescribed under the cardiovascular indication, became eligible after the 2024 FDA approval. Each plan places covered drugs on tiers, and semaglutide products typically land on specialty tiers. Specialty tier coinsurance ranges from 25% to 33% of the list price. At a list price of $1,300 per month, that coinsurance equals $325 to $430 monthly before the out-of-pocket cap applies.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge is a temporary federal program running from July 1, 2026, through December 31, 2027, that caps the monthly cost of certain GLP-1 weight-loss medications at $50 for eligible Medicare Part D beneficiaries. The $50 copay applies regardless of income level.
The program covers three specific medications: Wegovy (injection and tablet), Zepbound (KwikPen only), and Foundayo (oral tablet). Ozempic is not included in the Bridge program. The $50 payment does not count toward the annual Part D deductible or out-of-pocket limit. Single-dose Zepbound pens and Zepbound vials are not covered under this program. Patients do not need to enroll separately. Eligibility is determined at the pharmacy through Part D plan verification.
Who Qualifies for Medicare Semaglutide Coverage?
Eligibility for the Medicare GLP-1 Bridge requires active Medicare Part D drug coverage plus at least one BMI or health condition threshold, and patients must be at least 18 years of age. Multiple pathways exist based on BMI and comorbidities.
Patients already receiving GLP-1 drugs through Medicare for diabetes, sleep apnea, or fatty liver disease are not eligible for the Bridge program, but their existing coverage continues. Those covered through special plan types, including private fee-for-service plans, cost contract plans, or PACE organizations, are also ineligible. Standard Medicare Advantage plans with drug coverage and standalone Part D plans qualify.
What BMI Requirements Apply?
The Medicare GLP-1 Bridge sets three BMI thresholds, each paired with specific health conditions, to determine whether a beneficiary qualifies for the $50-per-month copay on weight-loss GLP-1 medications. BMI is calculated by the treating physician.
A BMI of 35 or higher qualifies a patient regardless of additional conditions. A BMI of 30 or higher qualifies a patient who also has certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease at stage 3a or above. A BMI of 27 or higher qualifies a patient with prediabetes or a history of heart attack, stroke, or blocked arteries in the legs or arms. Patients who do not know their BMI should ask their doctor to calculate it at the next visit.
What Health Conditions Make You Eligible?
Beyond BMI, Medicare recognizes specific cardiometabolic and vascular conditions as qualifying criteria that open coverage pathways for semaglutide and related GLP-1 medications under Part D and the Bridge program. Documentation from a physician is required.
Type 2 diabetes is the clearest qualifying condition, covered under standard Part D through Ozempic. Known cardiovascular disease paired with obesity or overweight qualifies under Wegovy’s FDA cardiovascular indication. Prediabetes at a BMI of 27 or higher qualifies under the Bridge program. Chronic kidney disease stage 3a or above at a BMI of 30 or higher also qualifies. Patients with multiple qualifying conditions should confirm coverage with their Part D plan before filling a prescription.
How Much Does Semaglutide Cost Under Medicare?
Without any coverage, semaglutide carries a list price that exceeds $1,000 per month, a cost barrier that has made GLP-1 medications inaccessible for millions of seniors on fixed incomes. Coverage scenarios vary widely by plan, condition, and program eligibility.
The Medicare GLP-1 Bridge offers the most predictable cost at $50 per month. Standard Part D coverage for semaglutide used in diabetes or cardiovascular disease places the drug on a specialty tier, where coinsurance applies. The Inflation Reduction Act caps annual out-of-pocket drug spending for Medicare beneficiaries at $2,000 for brand drugs starting in 2025. Manufacturer discount programs and coupons are illegal for Medicare beneficiaries under federal anti-kickback rules, so standard retail discounts do not apply.
What Are Out-of-Pocket Costs?
A senior without qualifying conditions pays the full retail price for semaglutide, which according to the manufacturer of Ozempic runs $1,027.51 per month for monthly injections, and Wegovy’s list price reaches approximately $1,300 per month. No Medicare plan reduces this without a covered diagnosis.
Seniors with a covered diagnosis face specialty tier coinsurance of 25% to 33% of the list price. At Wegovy’s list price, coinsurance costs $325 to $430 per month before reaching the annual cap. Once the $2,000 out-of-pocket cap is hit, Medicare covers 100% of remaining costs for the year. The Medicare Prescription Payment Plan, a monthly installment option, does not apply to Bridge program medications. Ready to get a proven weight loss plan that fits your budget and health profile.
How Does the $50 Bridge Program Work?
The Medicare GLP-1 Bridge applies automatically at the pharmacy for eligible Part D beneficiaries, capping the cost of covered GLP-1 weight-loss medications at $50 per month with no separate enrollment required. The Centers for Medicare and Medicaid Services determines eligibility.
The $50 copay covers one box of 4 Wegovy pens or one bottle of 30 Wegovy tablets per month. The copay does not count toward the Part D deductible. The copay does not count toward the annual $2,000 out-of-pocket limit, meaning it is a flat cost for the duration of the program. The Bridge program runs through December 31, 2027. Coverage after that date remains undetermined. Beneficiaries should enroll in the Wegovy Insider program for program updates.
What Are the Side Effects of Semaglutide for Seniors?
Semaglutide carries a well-documented side effect profile dominated by gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, which typically occur at the start of treatment or after dose increases. Most side effects are mild to moderate in severity.
Seniors face additional risks due to age-related physiological changes. Muscle loss is a concern with rapid weight reduction in older adults. Dehydration from GI symptoms can worsen kidney function. A family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is an absolute contraindication. Pancreatitis, gallbladder disease, and low blood sugar (particularly in diabetic patients on other medications) are documented adverse events. Our nutritionists at Eat Proteins recommend discussing all current medications with a physician before starting any GLP-1 treatment.
Who Should Not Use Semaglutide?
Patients with a personal or family history of medullary thyroid carcinoma must not use Wegovy or any semaglutide product because animal studies showed thyroid tumor formation, and the risk in humans has not been ruled out. MEN 2 is an additional absolute contraindication.
Patients who have had a serious allergic reaction to semaglutide or any ingredient in a Wegovy formulation must not use the drug. It is not known whether Wegovy injection is safe for children under 12 years or Wegovy tablets for anyone under 18. Seniors with severe renal impairment or a history of pancreatitis should discuss the risks carefully with their physician. In all cases, prior authorization from the Medicare plan is typically required before the first prescription is filled.
What Other Weight Loss Help Does Medicare Offer?
Original Medicare covers several non-drug weight management services, including annual wellness visits, obesity screenings, and behavioral counseling, at no out-of-pocket cost for members whose doctors accept Medicare. These services exist independent of drug coverage status.
Medicare Part B covers obesity screenings and behavioral counseling for beneficiaries with a BMI of 30 or higher. The Annual Wellness Visit, offered free once per year, creates a documented opportunity to discuss weight management with a physician. Medicare may also cover related conditions, such as diabetes prevention programs, for qualified patients. These services do not replace GLP-1 medication coverage but complement it, particularly for patients who do not yet meet the Bridge program’s BMI thresholds.
Does Medicare Cover Weight Loss Surgery?
Yes. Medicare covers bariatric surgery for members with a BMI of 35 or higher who also have at least one obesity-related health condition and who have tried other medical weight loss treatments without success. Surgery coverage is governed by Part A for inpatient procedures.
Coverage includes procedures such as gastric bypass and sleeve gastrectomy performed at Medicare-certified bariatric surgery centers of excellence. Coverage eligibility requires documentation of failed prior attempts at medically supervised weight loss. Recovery protocols and long-term dietary needs are part of the covered program. Seniors weighing both surgery and GLP-1 medications should compare long-term costs and health outcomes with their physician.
How Long Does Semaglutide Take to Show Results?
Weight loss from semaglutide typically begins within the first four weeks of treatment, though meaningful results accumulate over 16 to 68 weeks depending on dose, adherence, and individual metabolic response. Clinical trials show results continue to compound over time.
The STEP 1 trial showed patients lost an average of 14.9% of body weight over 68 weeks at the 2.4 mg weekly dose. Results at lower doses or shorter durations are proportionally smaller. Gastric emptying effects appear within days. Fat mass reduction accelerates as the dose is increased through the titration schedule. Patients who stop the medication without lifestyle changes typically regain a significant portion of lost weight within one year.
What Results Can Seniors Expect?
Seniors on semaglutide can expect modest but clinically meaningful weight loss alongside improvements in blood pressure, blood glucose levels, and cardiovascular risk markers, all of which are particularly valuable for older adults managing multiple conditions. Results vary by starting weight and adherence.
Average weight loss in clinical trials ranged from 10% to 15% of total body weight over approximately 16 months at therapeutic doses. For a 200-pound (91 kg) senior, that represents 20 to 30 pounds (9 to 14 kg). A reduction of 5% to 10% of body weight is considered clinically significant for improving metabolic markers. Muscle preservation through adequate protein intake and resistance training is essential for seniors to maintain functional strength during the weight loss period.
Want a Free Medicare Weight Loss Guide from Eat Proteins?
You have the facts. Now you need a plan. The Medicare rules around semaglutide change fast, eligibility depends on exact BMI and diagnosis details, and the $50 Bridge program closes at the end of 2027. Waiting costs you money.
The team at Eat Proteins put together a free guide built specifically for seniors navigating Medicare coverage for GLP-1 medications. It covers which conditions qualify, how to talk to your doctor, and exactly how to confirm your $50 Bridge program eligibility at the pharmacy. Get it sent straight to your inbox right now.
How Can Eat Proteins Help You Navigate Medicare Coverage?
The Eat Proteins approach combines evidence-based nutrition guidance with practical insurance navigation, helping seniors understand which qualifying conditions matter most for securing Medicare coverage of GLP-1 medications like semaglutide. The free guide is the starting point.
Our coaches at Eat Proteins specialize in high-protein dietary strategies that preserve muscle mass during GLP-1-assisted weight loss. This is especially important for seniors, where muscle preservation directly affects mobility and independence. The free plan includes a protein intake calculator, a 7-day meal guide optimized for GLP-1 users, and a Medicare coverage checklist. Sign up above to get it delivered immediately.